ClinicalTrials.gg
TerminatedNCT06438783Updated Dec 12, 2025

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

A Phase 1 interventional study of 1200mg of TQB2928 injection+Anlotinib and 1800mg of TQB2928 injection+Anlotinib in Osteosarcoma and Other Solid Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Terminated at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2024, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 60 studies in Osteosarcoma with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Osteosarcoma · China.

Enrollment
31st of 42
20 · median 44
Started
2024
with 11 others
Phase 1
10 of 60
7 open now
Registered
45th of 60
by date
Lead sponsor
1 of 60
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 60 studies in Osteosarcoma with a site in China, this one is the 31st largest by enrollment of the 42 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 in phase 1, and was the 45th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

22 of the 60 studies in Osteosarcoma with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Osteosarcoma with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other relapsed/metastatic solid tumors.

03

Conditions studied

  • Osteosarcoma
  • Other Solid Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathological diagnosis of high-grade osteosarcoma(cohort I),dedifferentiated liposarcoma or polytypic liposarcoma(cohort II),unsuitable for local treatment;
  • The requirements for front-line treatment received by subjects are as follows:

    1. Subjects with osteosarcoma have failed at least chemotherapy and are not suitable for re-receiving first-line chemotherapy ,or progression within 6 months of the end of first-line therapy;
    2. Subjects with dedifferentiated liposarcoma or polytype liposarcoma who have received at least first-line chemotherapy failure for recurrent/ sites or relapse during postoperative chemotherapy or within 6 months after treatment(considered first-line treatment failure).

Exclusion criteria

Exclusion Criteria:

  • History of hemolytic anemia from any cause (including Evans syndrome) within 3 months prior to first dosing;
  • Subjects with osteosarcoma or dedifferentiated liposarcoma/polytype liposarcoma who have previously used antiangiogenic tyrosine kinase inhibitors (TKI) or bevacizumab or its biosimilar, such as anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, fruquintinib;
  • Previous antibody or fusion protein or small molecule drug targeting 7 or Signal-regulatory protein α (SIRRP-α).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    1200mg of TQB2928 injection +Anlotinib

    21 days as a treatment cycle.

    Drug: 1200mg of TQB2928 injection+Anlotinib

  • Experimental
    1800mg of TQB2928 injection+Anlotinib

    21 days as a treatment cycle.

    Drug: 1800mg of TQB2928 injection+Anlotinib

Interventions

  • Drug1200mg of TQB2928 injection+Anlotinib

    TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).

  • Drug1800mg of TQB2928 injection+Anlotinib

    TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Progression-Free Survival (PFS) of 6 months

    Cohort 1: Kaplan-Meier method was used to plot the survival curve, in which the cumulative survival rate and 95% confidence interval corresponding to the progression-free survival time of 6 months were obtained.

    Time frame: Up to 6 months

  2. Cohort 2: Overall response rate (ORR)

    Cohort 2: The percentage of subjects with complete (CR) or partial response (PR) as determined by the investigator according to the RECIST 1.1 criteria.

    Time frame: Up to 6 months

Secondary outcomes

  1. Cohort 1: Progression-Free Survival (PFS) of 4 months

    Cohort 1: Survival curve was plotted using Kaplan-Meier method. In the curve, the corresponding cumulative survival rate and 95% confidence interval for progression-free survival of 4 months were obtained.

    Time frame: Up to 4 months

  2. Cohort 1: Overall response rate (ORR)

    Cohort 1: The percentage of subjects with complete (CR) or partial response (PR) as determined by the investigator according to the RECIST 1.1 criteria.

    Time frame: Baseline up to 96 weeks

  3. Cohort 2: Progression-Free Survival (PFS) of 6 months

    Cohort 2: Kaplan-Meier method was used to plot the survival curve with the corresponding cumulative survival rate and 95% confidence interval (95% CI) when the progression-free survival time was 6 months. The overall population and 2 dose groups were counted separately (including participants in the safe introduction period and the extended period).

    Time frame: Up to 6 months

  4. Progression-Free Survival (PFS) of Cohort 1 and Cohort 2

    The time between medication or random initiation and objective progression of disease or death from any cause, whichever comes first.

    Time frame: Up to 96 weeks

  5. Disease control rate (DCR) of Cohort 1 and Cohort 2

    The percentage of subjects with complete response (CR), partial response (PR), or stable disease (SD) for 6 weeks or more as determined by the investigator based on RECIST 1.1.

    Time frame: Up to 6 weeks

  6. Duration of response(DOR) of Cohort 1 and Cohort 2

    For subjects whose optimal response was complete response (CR) or partial response (PR), defined as from the date when tumor response was first documented to the date when disease progression was first documented or the date of death from any cause, whichever came first.

    Time frame: Baseline up to 96 weeks

  7. Overall survival (OS) of Cohort 1 and Cohort 2

    From randomization to the time of death from any cause.

    Time frame: Baseline up to 96 weeks

  8. Adverse event rate of Cohort 1 and Cohort 2

    Incidence and severity of adverse events (AES) and serious adverse events (SAEs), abnormal laboratory test indicators and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 96 weeks

  9. Incidence of Anti-drug antibody (ADA )and Neutralizing Antibody( NAb )

    The positive rates of immunogenicity (ADA and NAb) in subjects were summarized and descriptive statistical analysis was performed.

    Time frame: 30 minutes before administration on day 1 of cycles 1, 2, 4 and 8 (each cycle is 21 days), day 90 after the last administration (±7 days)

07

Study locations

5 sites
  • Beijing jishuitan hospital
    Beijing, Beijing Municipality 100035, China
  • Pekjing university people's hospital
    Beijing, Beijing Municipality 100044, China
  • Beijing cancer hospital
    Beijing, Beijing Municipality 100142, China
  • Hunan cancer hospital
    Changsha, Hunan 410031, China
  • Tianjin medical university cancer institute&hospital
    Tianjin, Tianjin Municipality 300181, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2024
First posted
Jun 3, 2024
StartActual
Feb 15, 2024
Primary completionActual
Jun 18, 2025
CompletionActual
Jun 18, 2025
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06438783
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Feb 15, 2024
Primary completion
Jun 18, 2025
Completion
Jun 18, 2025
Last update
Dec 12, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion